This report will highlight 10 important studies presented during ESMO 2014, and 4 small but promising future directions in the treatment of NSCLC. The presidential symposium featured two negative studies in a large cohort of non-small cell lung cancer (NSCLC) patients: the MAGRIT and IMPRESS. The other topics include immunotherapy, targeted treatment and biomarkers, development of new drugs in ALK-EML rearranged NSCLC, and prevention of cachexia in NSCLC. Lastly, an important study in malignant pleural mesothelioma (MPM) was presented.

(BELG J MED ONCOL 2014;8(4):152–7)